Kornimate/medical-research-clean huggingface dataset:
evaluation of daily hemodialysis with low dialysate flux in unscheduled patients with kidney injury admitted to hemodialysis

Conditions: Acute Kidney Injury; Kidney Failure, Chronic

Summary: the objective of the equodia study is to evaluate the hemodynamic stability of hemodialysis with low dialysate flow in patients requiring emergency hemodialysis in the context of acute kidney injury or unscheduled end-stage renal disease, not in intensive care, compared to conventional triweekly high-flow hemodialysis. short daily hemodialysis has excellent hemodynamic tolerance, which has already been confirmed by clinical experience. this modality, commonly used in the patient's home through new machines allowing a low dialysate flow purification technique, can prove to be an innovative, effective and safe alternative for patients admitted for hemodialysis in an unscheduled situation (acute kidney injury, unscheduled end-stage renal disease not followed). up to now, no studies have evaluated the use of short daily hemodialysis with low dialysate flow in patients with acute kidney injury or unscheduled end-stage renal disease, requiring the initiation of emergency extra-renal purification.


Eligibility criteria:
inclusion criteria: * male or female 18 years of age or older * patient requiring unscheduled hemodialysis for end-stage renal disease or acute kidney injury * patient able to understand the protocol * patient who has agreed to participate in the study and has given express oral consent * patient affiliated to a social security system exclusion criteria: * patient with more than one dialysis session * intensive care patient (need for vasoactive amine infusion, non-invasive ventilation, assisted ventilation) * patient participating in interventional clinical research involving a drug/medical device * patient under guardianship, curator, deprived of liberty * pregnant or breastfeeding patient, or with the ability to procreate without effective contraception * patient refusing to participate * patient unable to understand the protocol and/or give express oral consent
study of microcirculation during extracorporeal circulation in cardiac surgery

Conditions: Heart Diseases

Summary: the aim of the proposed study is to evaluate microcirculatory alterations in patients undergoing open heart surgery under extracorporeal circulation. positive clinical results evidenced with goal-directed perfusion and cerebral oximetry monitoring could be attributed to preserved microcirculation at tissue level.

the aim of the proposed study is to evaluate microcirculatory alterations in patients undergoing open heart surgery under extracorporeal circulation. microcirculatory changes during cardiac surgery have been investigated mainly during coronary procedures using the conventional extracorporeal circulation. there is no single study in the literature investigating microcirculatory alterations using a perioperative strategy of "physiologic" perfusion. positive clinical results evidenced with goal-directed perfusion and cerebral oximetry monitoring could be attributed to preserved microcirculation at tissue level. all patients will follow the same anaesthetic and perfusion protocol. the protocol for the evaluation of microcirculation will be based on: * cerebral near-infrared spectroscopy (rsco2) measurements (invos, covidien-medtronic inc.). * nirs-based cerebral autoregulation monitoring: analog arterial blood pressure signals will be digitized and then processed with the digital nirs signals using a personal computer and a special icm software (university of cambridge, cambridge, uk). monitoring cerebral autoregulation ensures adequate renal perfusion. hence, brain can be used not just as a target but also as an index organ indicating adequacy of perfusion. * somatic near-infrared spectroscopy (rsso2) measurements (invos, covidien-medtronic inc.). * sublingual mucosal microcirculation measurements during surgery using side dark field (sdf) imaging (microscan, microvision medical, amsterdam, the netherlands). all measurements will be performed at the following time points: t0: after induction of anaesthesia t1: after initiation of cardiopulmonary bypass t2: 10 minutes after cross- clamping the aorta t3: 10 minutes before removing the aortic cross-clamp t4: after weaning from extracorporeal circulation

Eligibility criteria:
inclusion criteria: * patients aged \> 18 and \< 85 years with coronary artery disease and/or aortic valve disease undergoing open heart surgery with accepted indications exclusion criteria: * patients undergoing emergency surgery * patients in preoperative cardiogenic shock with evidence of tissue malperfusion * patients \> 85 years of age * patients with severe peripheral vascular disease

Keywords: microcirculation cardiac surgery
registry and prevalence of gene mutation in korean patients with familial hypertrophic cardiomyopathy

Conditions: Familial Hypertrophic Cardiomyopathy

Summary: set the korean familial hypertrophic cardiomyopathy (kfhc) registry to study the prevalence of gene mutations in korean patients with familial hypertrophic cardiomyopathy


Eligibility criteria:
inclusion criteria: 1. left ventricular maximal wall thickness ≥ 15mm on echocardiography 2. hypertrophic cardiomyopathy patients' relatives exclusion criteria: 1. other cardiomyopathy or systemic disease (e.g. fabry disease, danon disease, glycogen storage disease) 2. who deny the study entrance, especially in patients' relatives
inhibition of non-histaminergic pruritus applied using 3 different pruritogens

Conditions: Itch

Summary: with this experiment, we want to use to investigate whether repeated application of emla cream as a tool to modulate non-histaminergic itching, which is produced using small needles from the plant mucuna pruriens (it is known that antihistamine does not attenuate this form of itch) and we want to compare the effect of short (1 hour) and prolonged (3 hours) application of emla. the sub-project takes place in 3 sessions over a period of 3 consecutive days (24 hours apart). all sessions will be identical.


Eligibility criteria:
inclusion criteria: * healthy men and women * 18-60 years * speak and understand english exclusion criteria: * pregnancy or lactation * drug addiction defined as any use of cannabis, opioids or other drugs * previous or current neurologic, musculoskeletal or mental illnesses that may affect the results (e.g. neuropathy, muscular pain in the upper extremities, etc.). * lack of ability to cooperate * current use of medications that may affect the trial such as antihistamine medications or pain killers. * skin diseases * hypersensitivity to papaya and mango fruit, cashew nuts and rubber latex * consumption of alcohol or painkillers 24 hours before the study days and between these * acute or chronic pain * participation in other trials within 1 week of study entry (4 weeks in the case of pharmaceutical trials) * known history of anaphylactic shock, or local allergy (contact dermatitis) to lidocaine, prilocaine or other local anaesthetics of the amide type.
an observational study to evaluate the incidence of macce according to time interval of taking medication in patients with acute coronary syndrome or cerebral infarction who received dapt for the secondary prevention and esomezol cap for the prevention of gastrointestinal bleeding

Conditions: Acute Coronary Syndrome or B Cerebral Infarction Requiring DAPT(Clopidogrel + Aspirin) for at Least 6 Months

Summary: this study is to evaluate the incidence rate of major adverse cardiocerebrovascular events(macce) in patients with acute coronary syndrome or cerebral infarction who received dapt for the secondary prevention and esomezol cap for the prevention of gastrointestinal bleeding.

this study was a multi-center, prospective, non-interventional, observational study of administering esomezol cap for the purpose of preventing gastrointestinal bleeding. data was collected from patients receiving routine treatment at hospitals in south korea. each patient visited the institution according to the protocol that designed the follow-up visits for six months to examine the safety of esomezol cap. this study approved by the institutions' irbs and was conducted in compliance with clinical research ethics regulations.

Eligibility criteria:
inclusion criteria: 1. age≥19 2. among patients who visited the hospital due to the onset or recurrence of acute coronary syndrome or cerebral infarction within 1 month prior to registration, patients who are expected to receive dapt(clopidogrel + aspirin) for at least 6 months, in combination with esomezol cap for the purpose of preventing gastrointestinal bleeding patients receiving or planning to receive treatment 3. subject who can written informed consent voluntarily exclusion criteria: 1) patients for whom use of esomezol cap is prohibited
primary immunodeficiencies in costa rican adults

Conditions: Primary Immune Deficiency in Adults

Summary: primary immunodeficiencies represent a underdiagnosed group of rare diseases which if diagnosed well and in time can be treated in an efficient manner and prevent complications that may affect the quality of patients life in an severe manner. neither in costa rica nor in central america studies or national registries regarding the prevalence and characterization of primary immunodeficiencies in adult patients exist up to now. this study reflects for the first time the epidemiologic situation of primary immunodeficiencies in a central american country, characterizing adult patients diagnosed with primary and idiopathic immune disorders treated in two specialized immunodeficiency clinics in costa rica.


Eligibility criteria:
inclusion criteria: * all patients from adult primary immunodeficiency clinics will be included. exclusion criteria: * patients with hiv * proven secondary immunodeficiencies.
anxiety with cancer in the elderly (ace): a cognitive-behavioral intervention

Conditions: Anxiety; Depression; Quality of Life

Summary: the purpose of this study is to examine the feasibility and acceptability of and patient adherence to a telephone-administered cognitive-behavioral therapy intervention for anxiety in older adults (65 years and older) with cancer and their primary informal caregiver. this study will also examine whether the intervention has a clinically significant impact on patient anxiety (primary outcome) and depression, distress, and quality of life (secondary outcomes).

this study is a single arm pre-post evaluation of a six-session telephone-administered cognitive-behavioral therapy (cbt) intervention for anxiety in older adults with cancer and their primary informal (unpaid) caregiver. the primary purposes of this study are to evaluate the feasibility of the intervention and study procedures, acceptability of the intervention to older adults with cancer and their primary informal caregiver, and patient and caregiver adherence to the intervention. the secondary purpose is to examine changes in patient and caregiver anxiety, depression, distress, and quality of life pre to post intervention to determine whether the intervention has a clinically significant impact on these outcomes. anxiety is the primary outcome; depression, distress, and quality of life are secondary outcomes. patients will be 65 years of age or older and will be recruited from the myeloma, lung, lymphoma, gynecologic, and gastrointestinal cancer clinics at a single institution. study measures will be administered by telephone prior to initiating the intervention (pre-intervention) and following intervention completion (post-intervention).

Eligibility criteria:
inclusion criteria: 1. patient age 65 years or older 2. diagnosis of cancer 3. patient and/or caregiver score of 8 or higher on the anxiety subscale of the hospital anxiety and depression scale 4. a primary informal caregiver who is willing and able to participate 5. patient and caregiver are able to communicate over the telephone 6. caregiver is age 21 years or older. exclusion criteria: 1. patient or caregiver is not fluent in english 2. patient or caregiver is too weak or cognitively impaired to participate in the intervention 3. patient or caregiver has received cbt since the patient's cancer diagnosis 4. patient or caregiver has an active major psychiatric condition such as schizophrenia 5. patient only experiences anxiety in the context of a specific medical procedure 6. patient or caregiver endorses active suicidal ideation

Keywords: cancer anxiety cognitive behavior therapy elderly caregivers
neurotrack virtual cognitive health study

Conditions: Subjective Cognitive Decline

Summary: the neurotrack virtual cognitive health study is a 12-month long, prospective study that aims to evaluate the impact of the neurotrack virtual cognitive health coaching program on cognitive ability, anxiety and depression, and lifestyle behaviors for individuals who show signs of subjective cognitive decline.


Eligibility criteria:
inclusion criteria: * ages 60-75 * individuals who show signs of subjective cognitive decline (assessed by scoring ≥ 1 on the subjective cognitive decline \[short form\] questionnaire and endorsing the personal worry item on the questionnaire) * have the ability to make and receive phone calls * have the ability to send and receive text messages * access to a desktop computer, video-teleconferencing and reliable internet connection * motivated to use a daily coaching program exclusion criteria: * significant history of mental illness, substance abuse, learning disability, or neurologic conditions * history of dementia * ophthalmologic/visual problems that prevent individual from viewing a computer screen at a normal distance (e.g., legal blindness, detached retinas, occlusive cataracts) * currently participating in a formal cognitive-training coaching program * currently pregnant
bile and bile duct/pancreatic duct brushings database for patients with pancreato-biliary stricture

Conditions: Pancreatic Duct Strictures; Biliary Duct Strictures

Summary: the purpose of this study is to create a long-term storage of bile and brushings of pancreato-biliary duct in patients diagnosed with pancreato-biliary stricture for future research. recently, a lot of research has been done to test for certain markers in the bile and brushings to detect cancer in a stricture. the samples will be used to measure biomarkers (proteins) in biliary diseases.

recently, a lot of research has been done to test for certain markers like fluorescence in situ hybridization (fish), digital image analysis (dia), and quantifiable morphometric results in biliary stricture brushings. recently, polysomy fish has been studied as a promising marker in predicting cancer in a pancreato-biliary stricture. many genetic, epigenetic, and protein alterations arise during pancreaticobiliary tumor process. the types of markers that have been commonly evaluated as diagnostic assays are mutations, chromosomal gains and losses, and dna methylation alterations. however there are only a few studies in this area. testing for these markers can help determine whether the narrowing or stricture in your bile duct is cancer or not.

Eligibility criteria:
inclusion criteria: * any patient diagnosed with pancreato-biliary stricture. * age \>18 years * ability to provide an informed consent exclusion criteria: * patients with altered mental status, who will not be able to provide an informed consent * pregnant women

Keywords: pancreas biliary stricture
neoadjuvant chemoradiotherapy and adjuvant chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in rectal cancer

Conditions: Rectal Neoplasms

Summary: standard treatment for locally advanced cancer of the rectum is preoperative chemoradiotherapy with 5-fluorouracil (5-fu) plus 4 cycles of postoperative chemotherapy with 5-fu. according to our previous study (cao/aro/aio-94, published in the new england journal of medicine 2004; 351:1731-40) this treatment results in only 6% of local failures, yet, still 36% of all patients develop distant metastasis. therefore, our new study (cao/aro/aio-04) incorporates new drugs, i.e. 5-fu + oxaliplatin, in an effort to improve the control of distant metastases. it is our hypothesis that the rate of disease free survival will improve by 5 to 8% after 3 years of follow-up.


Eligibility criteria:
inclusion criteria: * minimum age: 18 years * histologically proven, advanced primary carcinoma of the rectum (tumor ? 12cm from the anal verge, with clinically staged t3/4 or any node-positive disease * no prior therapy except a diverting stoma * ecog ps less than or equal 2 * adequate bone marrow function: leukocytes \> 3,5 x 10\^9/l absolute neutrophil count \> 1,5 x 10\^9/l platelet count \> 100 x 10\^9/l hemoglobin \> 10 g/dl * adequate hepatic function: total bilirubin \ 50 ml/min * written informed consent before randomization exclusion criteria: * pregnant or breast feeding women * fertile patients without adequate contraception during therapy * past or ongoing drug abuse or alcoholic excess * prior chemotherapy * prior radiotherapy to the pelvis * prior (within 4 weeks) or concurrent treatment with any other investigational agent * psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule * history of severe somatic or psychological diseases: - instable cardiac disease not well controlled with medication, myocardial infarction within the last 6 months:\* central nervous system disorders or psychiatric disability including dementia or epileptic disease; \* active uncontrolled intercurrent infections or sepsis * peripheral neuropathy \> 2 (nci ctc ae grading) * previous or concurrent malignancies, with the exception of adequately treated basal cell carcinoma of the skin or in situ carcinoma of the cervix. the inclusion of patients with other adequately treated tumors within the last 5 years has to be discussed with the principal investigator * chronic diarrhea (\> nci ctc ae-grad 1) * known allergy to substances containing platinum compounds * concurrent use of the antiviral agent sorivudine or chemically related analogues * known deficiency of dehydropyrimidindehydrogenase (dpd)
study evaluating benefix in patients with haemophilia b, previously treated with plasma derived factor ix

Conditions: Hemophilia B

Summary: the purpose of this study is to collect data around the period of the conversion from plasma-derived factor ix (pdfix) to benefix. the main information collected will be: a retrospective history of the bleedings in the 3-month period before the conversion, the recovery with pdfix just before the conversion and with benefix just after the conversion, and a prospective history of the bleedings in the 3 month period following the conversion.

the switch to benefix has already been decided by the investigator. patients will be followed up to 3 months after the switch.

Eligibility criteria:
inclusion criteria: * moderately to severe haemophilia b patient (fix activity \< or equal to 2%) for whom the switch from pdfix to benefix has already been decided by the investigator * previously treated patients (ptp) with \> or equal to 150 ed to any fix product * male patients, aged \> or equal to 12 years * absolute cd4 count \> or equal to 300/microl * normal platelet count (\> or equal to 100 000/microl) * patient is in a non-bleeding state and has not received any coagulation fix within five (5) days of recovery * written informed consent obtained prior to study entry (for patients aged \< 18 years, parents' signature or subject legally acceptable representative obtained prior to study entry) exclusion criteria * any other known bleeding disorder in addition to haemophilia b * history of, or current detectable factor ix inhibitor (\> or equal to 0.6 bu by bethesda inhibitor assay) * history of anaphylaxis to any coagulation factor ix * patient with a known hypersensitivity to hamster protein * patient with a hypersensitivity to the active substance or to any of the excipients * patient unable to be off fix replacement therapy for at least 5 days without bleeding patient with hepatic or renal impairment (alt \[sgpt\] and ast \[sgot\] \> 5 x upper limit normal (uln), total bilirubin \> 20mg/l, albumin \ 1.25 x uln, serum creatinine \> 1.25 x uln) * treatment with any investigational drug or device within the past 30 days * any condition that, in the investigator's judgment, makes participation in the study not advisable
mit intensive treatment study

Conditions: Stroke; Aphasia; Motor Speech

Summary: this study is examining the use of intensive melodic intonation therapy and video feedback as a means of aiding individuals with nonfluent aphasia and co-occurring motor speech impairments. individuals with nonfluent aphasia have difficulty with language, particularly with word retrieval.


Eligibility criteria:
inclusion criteria: * fluent english speakers * sustained a left-hemisphere stroke * presents with language and motor speech impairments exclusion criteria: * • history of learning disability prior to accident (per patient report) * uncorrected auditory or visual impairments * not meeting the criteria of stroke * failure to provide evidence of stroke diagnosis (medical record history) * history of psychiatric disorder
incidental discovery of pulmonary emboli via ct scan: impact of detections on patient care and resulting complications

Conditions: Pulmonary Embolism

Summary: in recent years, with an increase in the frequency of ct examinations, there has also been an increase in the random discovery of pulmonary emboli, often small, as part of examinations performed for other indications. most of the literature so far deals with the discovery of such findings mainly in oncological patients, and there is relatively little information regarding the frequency of such random discovery in other patient populations. specifically in the intensive care patient population, we have not yet found any study that examined the detection rates of these findings. also, there is no consensus regarding how these random findings should be treated from a therapeutic point of view (whether to start treatment with full anticoagulation, and if so, for what period of time). random pulmonary embolism is often discovered as part of a ct scan done to assess acute lung disease or lung cancer staging. in a study done in oncology patients, 385 chest ct examinations were examined, with a random discovery of pulmonary emboli at a rate of 2.6% . a larger analysis of 8 studies involving 8491 cancer patients found a slightly higher incidence of 3.6%. we would like to check the rate of pulmonary emboli that were randomly discovered in chest ct examinations performed in the intensive care unit for other indications, and the consequences of discoveries - ie starting anti-coagulant treatment and whether there were any complications for starting such treatment (bleeding).


Eligibility criteria:
inclusion criteria: all patients who were admitted to the icu between 8/2020 and 8/2024 and underwent chest ct during icu stay - exclusion criteria: missing information -